5th NovAliX Conference

Biophysics in Drug Discovery 2018

Developing the Synergy between Biophysics and Medicinal Chemistry to Deliver Better Drugs

 Boston, USA    June 13-15, 2018

Programme


12:30

Registration

13:45

Welcome Address

Session 1: Hot Topics

Session Chair

Dr Chaohong SUN
ABBVIE, North Chicago, United States

14:00

OC01 - Making Off-Rate Screening in FBDD More Amenable For Fast Dissociating Compounds

Dr Menachem GUNZBURG
MONASH UNIVERSITY, Parkville, Australia

14:15

OC02 - Novel Active Site and Allosteric Site Binders Identified for FPPS Of T. cruzi

Ms Joy PETRICK
NOVARTIS, Basel, Switzerland

14:30

OC03 - Dynamic Single-Molecule Approaches to Accelerate the Development of More Efficient Drugs

Dr Gerrit SITTERS
LUMICKS, Amsterdam, The Netherlands

14:45

OC04 - Quantitative Irreversible Tethering (QIT) for Covalent Ligand Discovery

Dr Gregory CRAVEN
IMPERIAL COLLEGE LONDON, London, United Kingdom

15:00

OC05 - Large Protein Conformational Changes in Pi3kgamma Linked to the Binding of a New Class of Highly Selective Inhibitors

Dr Göran DAHL
ASTRAZENECA, Mölndal, Sweden

15:15

IL01 - Binding Kinetics and Thermodynamics in Drug Discovery

Dr Chaohong SUN
ABBVIE, North Chicago, United States

15:45

Coffee Break

Session 2 : Target Engagement

Session Chair

Dr Daniel WYSS
MERCK, Kenilworth, United States

16:25

IL02 - Chemical Probes for Epigenetic Targets

Prof. Masoud VEDADI
STRUCTURAL GENOMICS CONSORTIUM, Toronto, Canada

16:55

Exhibitor Short Presentation: Bruker
Development and Proof-of-Concept of a New Flow-through System for High Resolution NMR to Evaluate Biologics-producing Cell Lines and Their Growth Environments

Dr Jason S. WOOD
BRUKER BIOSPIN, Billerica, United States

17:05

Exhibitor Short Presentation: Creoptix
The Wave of the Future in Kinetics

Dr Matyas VEGH
CREOPTIX AG, Wädenswil, Switzerland

17:15

OC06 - Quantification of Target Occupancy in Cells and Tumor Tissue Using FCCS

Dr Frank BECKER
INTANA BIOSCIENCE GMBH, Planegg, Germany

17:30

IL03 - How to Be Selectively Promiscuous

Prof. Jack TAUNTON
UNIVERSITY OF CALIFORNIA, San Francisco, United States

Keynote Lecture

Session Chair

Dr Daniel WYSS
MERCK, Kenilworth, United States

18:00

KL01 - From Simulations of Biomolecules to Fighting Diseases

Prof. Martin KARPLUS
UNIVERSITY OF STRASBOURG, FRANCE & HARVARD UNIVERSITY, Cambridge, United States

19:00

Welcome Reception

20:30

End of the Day

08:30

Registration

Session 3 : Cryo-EM

Session Chair

Dr Bridget CARRAGHER
NEW YORK STRUCTURAL BIOLOGY CENTER, New York, United States

09:00

IL04 - How Low Can You Go? Size and Resolution Limits Using Conventional Cryo-EM

Dr Gabriel LANDER
THE SCRIPPS RESEARCH INSTITUTE, San Diego, United States

09:30

IL05 - Cryo-EM for Characterization and Structure Based Drug Design

Dr Bridget CARRAGHER
NEW YORK STRUCTURAL BIOLOGY CENTER, New York, United States

10:00

Coffee Break

Session 3 (continued) : Cryo-EM

10:30

OC07 - Cryo-EM to Address Intractable Targets in Drug Discovery

Dr Hervé REMIGY
THERMO FISHER SCIENTIFIC, Eindhoven, The Netherlands

10:45

OC08 - Strength of Cryo-EM in Drug Discovery: One Could Always See Something

Dr Wen-ti LIU
NOVALIX, Illkirch, France

11:00

IL06 - Single Particle Cryo-EM Structure of the Insulin Receptor:Insulin Complex

Dr Giovanna SCAPIN
MERCK & CO. INC (MSD), Whitehouse Station, United States

11:30

Poster Session

12:30

Lunch & Networking

Session 4 : Membrane Proteins

Session Chair

Dr Dan ERLANSON
CARMOT THERAPEUTICS, San Francisco, United States

14:00

IL07 - New Tools Reveal Mechanisms of Allosteric Coupling in Human GPCRs

Dr Matthew EDDY
UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, United States

14:30

Exhibitor Short Presentation: Pall ForteBio
Dissecting Biomolecular Interactions - Pall ForteBio’s Next Gen SPR and BLI Label-Free Platforms: Providing Faster and Easier Solutions to Your Emerging Applications

Mr Bob DASS
PALL FORTEBIO, Menlo Park, United States

14:40

OC09 - Enabling NMR-Based Fragment Screening Using Stabilized Native GPCR: Case Study of Adenosine Receptor

Dr Anass JAWHARI
CALIXAR, Lyon, France

14:55

OC10 - Crystal Structures of Human Glycine Receptor Alpha3 Bound to a Novel Class of Analgesic Potentiators

Dr Xin HUANG
AMGEN, Cambridge, United States

15:10

IL08 - Structural Insight into Allosteric Modulation of GPCRs

Dr Miles CONGREVE
HEPTARES, Welwyn Garden City, United Kingdom

15:40

Coffee Break

Session 5 : Protein-Protein Interactions

Session Chair

Dr MariJean EGGEN
ELI LILLY, Indianapolis, United States

16:20

IL09 - Design Considerations for Synthetic Macrocycles in Drug Discovery

Prof. Adrian WHITTY
BOSTON UNIVERSITY, Boston, United States

16:45

OC11 - Use of Complementary Biophysical Methods to Characterize Ligand Binding to IL-17A

Dr Parag SAHASRABUDHE
PFIZER, Groton, United States

17:00

OC12 - Systematic Development of Small Molecules to Inhibit Specific Microscopic Steps of α-Synuclein Aggregation in Parkinson’s Disease

Ms Roxine STAATS
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom

17:15

IL10 - Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction

Dr Shilin XU
UNIVERSITY OF MICHIGAN, Michigan, United States

18:00

Posters & Drinks

19:30

End of the Day

20:00

Conference Dinner

08:30

Registration

Session 6 : Biotherapeutics

Session Chair

Dr Jim BRYSON
BRISTOL-MYERS-SQUIBB, Princeton, United States

09:00

IL11 - Attacking the Cancer Cell Surface-ome with Recombinant Antibodies

Prof. Jim WELLS
UCSF, San Francisco, United States

09:30

Exhibitor Short Presentation: Sierra Sensors
Controlling Throughput for SPR

Dr Christopher WHALEN
SIERRA SENSORS, Greenville, United States

09:40

IL12 - Multi-Specific Designer Proteins for Tumor Therapeutics

Dr Karyn T. O'NEIL
ARō BIOTHERAPEUTICS, Philadelphia, United States

10:10

Coffee Break

Session 6 (continued) : Biotherapeutics

10:40

Exhibitor Short Presentation: WuXi AppTec
Crelux – A Fully Integrated Offering, from Protein to Screen, Through Crystallography Confirmation and Beyond.

Dr Thomas WALDMANN
CRELUX, A WUXI APPTEC COMPANY, Martinsried, Germany

10:50

IL13 - Emerging Higher Order Structure Techniques in Biotherapeutics Development

Dr Tapan K. DAS
BRISTOL-MYERS SQUIBB, New York, United States

11:20

Poster Prizes and Closing Remarks

11:45

Farewell Lunch & Networking

13:00

End of the Conference